Section of Inflammatory Bowel Disease and Inflammatory Bowel Disease Center, Division of Digestive Diseases, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA.
Gastroenterology. 2010 Jun;138(7):2457-67, 2467.e1-5. doi: 10.1053/j.gastro.2010.02.055. Epub 2010 Mar 3.
BACKGROUND & AIMS: The corticotrophin-releasing hormone (CRH) family of peptides modulates intestinal inflammation and the CRH receptor 2 (CRHR2) suppresses postnatal angiogenesis in mice. We investigated the functions of CRHR1 and CRHR2 signaling during intestinal inflammation and angiogenesis.
The activities of CRHR1 and CRHR2 were disrupted by genetic deletion in mice or with selective antagonists. A combination of in vivo, ex vivo, and in vitro measures of angiogenesis were used to determine their activity. CRHR1(-/-) mice and CRHR2(-/-) mice with dextran sodium sulfate-induced colitis were analyzed in comparison with wild-type littermates (controls).
Colitis was significantly reduced in mice in which CRHR1 activity was disrupted by genetic deletion or with an antagonist, determined by analyses of survival rate, weight loss, histological scores, and cytokine production. Inflammation was exacerbated in mice in which CRHR2 activity was inhibited by genetic deletion or with an antagonist, compared with controls. The inflamed intestines of CRHR1(-/-) mice had reduced microvascular density and expression of vascular endothelial growth factor (VEGF)-A, whereas the intestines of CRHR2(-/-) mice had increased angiogenesis and VEGF-A levels. An antagonist of VEGFR2 activity alleviated colitis in CRHR2(-/-) mice. Ex vivo aortic vessel outgrowth was reduced when CRHR1 was deficient but increased when CRHR2 was deficient. The CRHR1 preferred agonist CRH stimulated tube formation, proliferation, and migration of cultured intestinal microvascular endothelial cells by phosphorylating Akt, whereas the specific CRHR2 agonist Urocortin III had opposite effects.
CRHR1 promotes intestinal inflammation, as well as endogenous and inflammatory angiogenesis whereas CRHR2 inhibits these activities.
促肾上腺皮质激素释放激素(CRH)家族肽调节肠道炎症,CRH 受体 2(CRHR2)抑制小鼠出生后的血管生成。我们研究了 CRHR1 和 CRHR2 信号在肠道炎症和血管生成中的作用。
通过基因敲除或选择性拮抗剂破坏 CRHR1 和 CRHR2 的活性。使用体内、体外和体外测量的血管生成组合来确定它们的活性。用葡聚糖硫酸钠诱导结肠炎分析 CRHR1(-/-) 小鼠和 CRHR2(-/-) 小鼠与野生型同窝仔鼠(对照)的差异。
通过基因敲除或用拮抗剂破坏 CRHR1 活性,可显著降低 CRHR1 活性的小鼠的存活率、体重减轻、组织学评分和细胞因子产生的结肠炎,与对照相比,CRHR2 活性受抑制的小鼠的炎症加重。CRHR1(-/-) 小鼠的发炎肠道微血管密度和血管内皮生长因子(VEGF)-A 表达降低,而 CRHR2(-/-) 小鼠的血管生成和 VEGF-A 水平增加。VEGFR2 活性拮抗剂缓解了 CRHR2(-/-) 小鼠的结肠炎。当 CRHR1 缺乏时,主动脉血管外生减少,而当 CRHR2 缺乏时,主动脉血管外生增加。CRHR1 优先激动剂 CRH 通过磷酸化 Akt 刺激培养的肠道微血管内皮细胞的管形成、增殖和迁移,而特异性 CRHR2 激动剂 Urocortin III 则有相反的作用。
CRHR1 促进肠道炎症以及内源性和炎症性血管生成,而 CRHR2 抑制这些活性。